WebOct 13, 2024 · Alnylam is committed to accepting challenges to improve the health of humanity, believing that we can, as a company and more than 1500 employees, have a positive impact on the health and well being of the world beyond our core mission of discovering and developing innovative medicines. WebAlnylam® — Who We Are WHO WE ARE Our commitment to innovation and excellence is reflected in everything we do, earning us a leadership position in both the science and business of RNAi therapeutics that is recognized worldwide. We strongly believe in the power of a positive culture as a key differentiator for individual and business success.
Alnylam R&D Day 2024 - Alnylam
WebApr 3, 2024 · 05 Oct, 2024 Alnylam Presents at OTS 2024 Annual Meeting. We presented on platform and clinical results at the Oligonucleotide Therapeutics Society (OTS) 2024 … Web310 Fourth Avenue South. Minneapolis, MN 55415. Phone: 612.455.0502. Fax: 612.455.0501. [email protected]. www.trepanierlaw.com. Minnesota Non … libgdx learning
Alnylam Pharmaceuticals, Inc. Patient Education Liaison
WebMar 30, 2024 · We presented non-clinical results on ALN-APP*, our investigational RNAi therapeutic for the treatment of Alzheimer’s disease and cerebral amyloid angiopathy at AD/PD 2024 Advances in Science & Therapy International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders, held on March 28-April 1 in … WebDec 3, 2014 · Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is leading the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics as genetic medicines, including programs as part of the company's "Alnylam 5x15™" product strategy. WebApr 10, 2024 · The Investor Relations website contains information about Alnylam Pharmaceuticals, Inc.'s business for shareholders, potential investors, and financial … mchw live service